It forms a stable complex with DNA and interferes with the synthesis of nucleic acids. It is a cell-cycle nonspecific agent, but its cytotoxic effects are most marked on cells in the S-phase. It also has immunosuppressant action, and in addition has antibacterial effect.

Acute lymphocytic and acute granulocytic leukaemias. Acute myeloblastic leukaemia. Rhabdomyosarcoma and disseminated neuroblastoma.

Hypersensitivity to Daunorubicin or any component, CHF or arrhythmias, preexisting bone marrow suppression. Previous full cumulative doses of doxorubicin and / or extravasation.

Nausea, vomiting, bone marrow depression, stomatitis, alopecia, rash, hyperpigmentation, cardiotoxicity, CHF, fever and chills. Diarrhoea, severe local tissue damage and necrosis on extravasation. Anaphylactoid reaction, red urine (not haematuria).

Cardiac, haematological monitoring. Hepatic, renal impairment, children, extravasation.

Immunisation with live vaccines not recommended as daunorubicin is immunosuppressant.

Reconstitute vial with 4ml water for injection to make 5mg/ml solution. Dilute requisite dose with infusion fluid to a concentration of 1mg/ml and infuse over 20 mins.

Elimination half-life of daunorubicin 18.6 hours. Its metabolite 26.7 hours.

20mg Inj., 1 vial per box.

  
*  for the use of a registered Medical practitioner or a Hospital or a Laboratory only.

[Go Back to the Export product list]

Shree  Ganesh  Pharmaceuticals
Mumbai - India.
  
Web site :  http://www.sgpharma.com             E-mail  :  exports@sgpharma.com

Disclaimer : This guide is provided for information purposes only, and for use of a registered medical practitioner or a hospital or a laboratory only. The authors, webmaster, or respective references / links are no way responsible for the content of the information. Although a concerted effort has been made to ensure the validity of the information contained in this document, we give no assurance for the accuracy of the information in this documents.